Multicenter analysis on the value of standard (chemo)radiotherapy in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction.
AEG
Adenocarcinoma
Chemoradiation
Elderly patients
Esophageal cancer
Gastroesophageal Junction tumor
Radiotherapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
04 Mar 2024
04 Mar 2024
Historique:
received:
31
10
2023
accepted:
30
01
2024
medline:
4
3
2024
pubmed:
4
3
2024
entrez:
3
3
2024
Statut:
epublish
Résumé
To assess the tolerability and oncological results of chemoradiation in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction. This multi-center retrospective analysis included 86 elderly patients (≥ 65 years) with esophageal or gastroesophageal junction adenocarcinoma (median age 73 years; range 65-92 years) treated with definitive or neoadjuvant (chemo)radiotherapy. The treatment was performed at 3 large comprehensive cancer centers in Germany from 2006 to 2020. Locoregional control (LRC), progression-free survival (PFS), distant metastasis-free survival (DMFS), overall survival (OS), and treatment-associated toxicities according to CTCAE criteria v5.0 were analyzed, and parameters potentially relevant to patient outcomes were evaluated. Thirty-three patients (38%) were treated with neoadjuvant chemoradiation followed by surgery, while the remaining patients received definitive (chemo)radiation. The delivery of radiotherapy without dose reduction was possible in 80 patients (93%). In 66 patients (77%), concomitant chemotherapy was initially prescribed; however, during the course of therapy, 48% of patients (n = 32) required chemotherapy de-escalation due to treatment-related toxicities and comorbidities. Twenty-nine patients (34%) experienced higher-grade acute toxicities and 14 patients (16%) higher-grade late toxicities. The 2-year LRC, DMFS, PFS, and OS amounted to 72%, 49%, 46%, and 52%, respectively. In multivariate analysis, neoadjuvant chemoradiation followed by surgery was shown to be associated with significantly better PFS (p = 0.006), DMFS (p = 0.006), and OS (p = 0.004) compared with all non-surgical treatments (pooled definitive radiotherapy and chemoradiation). No such advantage was seen over definitive chemoradiation. The majority of patients with neoadjuvant therapy received standard chemoradiotherapy without dose reduction (n = 24/33, 73%). In contrast, concurrent chemotherapy was only possible in 62% of patients undergoing definitive radiotherapy (n = 33/53), and most of these patients required dose-reduction or modification of chemotherapy (n = 23/33, 70%). In our analysis, omission of chemotherapy or adjustment of chemotherapy dose during definitive radiotherapy was necessary for the overwhelming majority of elderly esophageal cancer patients not eligible for surgery, and hence resulted in reduced PFS and OS. Therefore, optimization of non-surgical approaches and the identification of potential predictive factors for safe administration of concurrent chemotherapy in elderly patients with (gastro)esophageal adenocarcinoma is required.
Sections du résumé
BACKGROUND
BACKGROUND
To assess the tolerability and oncological results of chemoradiation in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction.
METHODS
METHODS
This multi-center retrospective analysis included 86 elderly patients (≥ 65 years) with esophageal or gastroesophageal junction adenocarcinoma (median age 73 years; range 65-92 years) treated with definitive or neoadjuvant (chemo)radiotherapy. The treatment was performed at 3 large comprehensive cancer centers in Germany from 2006 to 2020. Locoregional control (LRC), progression-free survival (PFS), distant metastasis-free survival (DMFS), overall survival (OS), and treatment-associated toxicities according to CTCAE criteria v5.0 were analyzed, and parameters potentially relevant to patient outcomes were evaluated.
RESULTS
RESULTS
Thirty-three patients (38%) were treated with neoadjuvant chemoradiation followed by surgery, while the remaining patients received definitive (chemo)radiation. The delivery of radiotherapy without dose reduction was possible in 80 patients (93%). In 66 patients (77%), concomitant chemotherapy was initially prescribed; however, during the course of therapy, 48% of patients (n = 32) required chemotherapy de-escalation due to treatment-related toxicities and comorbidities. Twenty-nine patients (34%) experienced higher-grade acute toxicities and 14 patients (16%) higher-grade late toxicities. The 2-year LRC, DMFS, PFS, and OS amounted to 72%, 49%, 46%, and 52%, respectively. In multivariate analysis, neoadjuvant chemoradiation followed by surgery was shown to be associated with significantly better PFS (p = 0.006), DMFS (p = 0.006), and OS (p = 0.004) compared with all non-surgical treatments (pooled definitive radiotherapy and chemoradiation). No such advantage was seen over definitive chemoradiation. The majority of patients with neoadjuvant therapy received standard chemoradiotherapy without dose reduction (n = 24/33, 73%). In contrast, concurrent chemotherapy was only possible in 62% of patients undergoing definitive radiotherapy (n = 33/53), and most of these patients required dose-reduction or modification of chemotherapy (n = 23/33, 70%).
CONCLUSIONS
CONCLUSIONS
In our analysis, omission of chemotherapy or adjustment of chemotherapy dose during definitive radiotherapy was necessary for the overwhelming majority of elderly esophageal cancer patients not eligible for surgery, and hence resulted in reduced PFS and OS. Therefore, optimization of non-surgical approaches and the identification of potential predictive factors for safe administration of concurrent chemotherapy in elderly patients with (gastro)esophageal adenocarcinoma is required.
Identifiants
pubmed: 38433231
doi: 10.1186/s13014-024-02414-9
pii: 10.1186/s13014-024-02414-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
28Informations de copyright
© 2024. The Author(s).
Références
Rubenstein JH, Shaheen NJ. Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology. 2015;149(2):302-317.e1.
doi: 10.1053/j.gastro.2015.04.053
pubmed: 25957861
Frederik HJ, Lars P, Mohr DA, Toft SH, Peter FJ. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–83.
doi: 10.1056/NEJMoa1103042
Wu AH, Tseng CC, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer. 2003;98(5):940–8.
doi: 10.1002/cncr.11568
pubmed: 12942560
Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825–31.
doi: 10.1056/NEJM199903183401101
pubmed: 10080844
Turati F, Tramacere I, La Vecchia C, Negri E. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol. 2013;24(3):609–17.
doi: 10.1093/annonc/mds244
pubmed: 22898040
Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P, et al. Ten-Year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39(18):1995–2004.
doi: 10.1200/JCO.20.03614
pubmed: 33891478
Cunningham D. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
doi: 10.1056/NEJMoa055531
pubmed: 16822992
Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. JCO. 2011;29(13):1715–21.
doi: 10.1200/JCO.2010.33.0597
Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.
doi: 10.1016/S1470-2045(15)00040-6
pubmed: 26254683
van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.
doi: 10.1056/NEJMoa1112088
pubmed: 22646630
Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. The Lancet. 2019;393(10184):1948–57.
doi: 10.1016/S0140-6736(18)32557-1
Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–203.
doi: 10.1056/NEJMoa2032125
pubmed: 33789008
Stroes CI, Schokker S, Creemers A, Molenaar RJ, Hulshof MCCM, van der Woude SO, et al. Phase II feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2–positive esophageal adenocarcinoma: TRAP study. JCO. 2020;38(5):462–71.
doi: 10.1200/JCO.19.01814
Hulshof MCCM, Geijsen ED, Rozema T, Oppedijk V, Buijsen J, Neelis KJ, et al. Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO Study). JCO. 2021;39(25):2816–24.
doi: 10.1200/JCO.20.03697
Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). JAMA. 1999;281(17):1623–7.
doi: 10.1001/jama.281.17.1623
pubmed: 10235156
Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15(3):305–14.
doi: 10.1016/S1470-2045(14)70028-2
pubmed: 24556041
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.
doi: 10.3322/caac.21590
Motoyama S, Maeda E, Iijima K, Anbai A, Sato Y, Wakita A, et al. Differences in treatment and survival between elderly patients with thoracic esophageal cancer in metropolitan areas and other areas. Cancer Sci. 2021;112(10):4281–91.
doi: 10.1111/cas.15070
pubmed: 34288283
pmcid: 8486216
Won E, Ilson DH. Management of localized esophageal cancer in the older patient. Oncologist. 2014;19(4):367–74.
doi: 10.1634/theoncologist.2013-0178
pubmed: 24664485
pmcid: 3983810
Mantziari S, Teixeira Farinha H, Bouygues V, Vignal JC, Deswysen Y, Demartines N, et al. Esophageal cancer in elderly patients, current treatment options and outcomes; a systematic review and pooled analysis. Cancers. 2021;13(9):2104.
doi: 10.3390/cancers13092104
pubmed: 33925512
pmcid: 8123886
Xia X, Gao Q, Ge X, Liu Z, Di X, Sun X, et al. Chemoradiotherapy is superior to radiotherapy alone in esophageal cancer patients older than 65 years: a propensity score-matched analysis of the SEER database. Front Oncol. 2021;7(11): 736448.
doi: 10.3389/fonc.2021.736448
Jingu K, Numasaki H, Toh Y, Nemoto K, Uno T, Doki Y, et al. Chemoradiotherapy and radiotherapy alone in patients with esophageal cancer aged 80 years or older based on the comprehensive registry of esophageal cancer in Japan. Esophagus. 2020;17(3):223–9.
doi: 10.1007/s10388-020-00725-w
pubmed: 32088786
Yang Y, Chen M, Xie J, Ji Y, Sheng L, Qiu G, et al. Treatment patterns and outcomes of elderly patients with potentially curable esophageal cancer. Front Oncol. 2022;14(12): 778898.
doi: 10.3389/fonc.2022.778898
Suzuki G, Yamazaki H, Aibe N, Masui K, Kimoto T, Shimizu D, et al. Definitive radiotherapy for older patients aged ≥75 years with localized esophageal cancer. In Vivo. 2019;33(3):925–32.
doi: 10.21873/invivo.11560
pubmed: 31028218
pmcid: 6559920
Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593–8.
doi: 10.1056/NEJM199206113262403
pubmed: 1584260
Bostel T, Akbaba S, Wollschläger D, Mayer A, Nikolaidou E, Murnik M, et al. Chemoradiotherapy in geriatric patients with squamous cell carcinoma of the esophagus: multi-center analysis on the value of standard treatment in the elderly. Front Oncol. 2023;3(13):1063670.
doi: 10.3389/fonc.2023.1063670
Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. JCO. 2007;25(10):1160–8.
doi: 10.1200/JCO.2005.04.7118
Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. JCO. 2005;23(10):2310–7.
doi: 10.1200/JCO.2005.00.034
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation therapy oncology group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–74.
doi: 10.1200/JCO.2002.20.5.1167
pubmed: 11870157
Mayer A, Wenzel W, Wollschläger D, Bostel T, Krüger M, Matthias C, et al. Adjuvant chemoradiotherapy in elderly patients with head and neck cancer: a monoinstitutional, two-to-one pair-matching analysis. Strahlenther Onkol. 2022;198(2):159–70.
doi: 10.1007/s00066-021-01890-2
pubmed: 35037950
pmcid: 8789714
Haehl E, Rühle A, David H, Kalckreuth T, Sprave T, Stoian R, et al. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly? Radiat Oncol. 2020;15(1):31.
doi: 10.1186/s13014-020-1481-z
pubmed: 32019576
pmcid: 7001207
Ji Y, Du X, Zhu W, Yang Y, Ma J, Zhang L, et al. Efficacy of concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: a multicenter randomized phase 3 clinical trial. JAMA Oncol. 2021;7(10):1459–66.
doi: 10.1001/jamaoncol.2021.2705
pubmed: 34351356
Lv H, Chao C, Wang B, Wang Z, Qian Y, Zhang X. The effect of surgery plus chemoradiotherapy on survival of elderly patients with stage II-III esophageal cancer: a SEER-based demographic analysis. Cancer Med. 2021;10(23):8483–96.
doi: 10.1002/cam4.4352
pubmed: 34800005
pmcid: 8633220
Jingu K, Takahashi N, Umezawa R, Yamamoto T, Takeda K, Suzuki Y, et al. The benefit of concurrent chemotherapy with radiotherapy for esophageal cancer is limited in Asian patients aged 80 years or older: a SEER database analysis. Esophagus. 2022;19(4):653–9.
doi: 10.1007/s10388-022-00938-1
pubmed: 35779138
Cooper L, Dezube AR, De León LE, Kucukak S, Mazzola E, Dumontier C, et al. Outcomes of trimodality CROSS regimen in older adults with locally advanced esophageal cancer. Eur J Surg Oncol. 2021;47(10):2667–74.
doi: 10.1016/j.ejso.2021.04.013
pubmed: 33895020
pmcid: 8448942
Gaber CE, Shaheen NJ, Edwards JK, Sandler RS, Nichols HB, Sanoff HK, et al. Trimodality therapy vs definitive chemoradiation in older adults with locally advanced esophageal cancer. JNCI Cancer Spectrum. 2022;6(6):pkac069.
doi: 10.1093/jncics/pkac069
pubmed: 36205723
pmcid: 9623425
Chow R, Chiu N, Bruera E, Krishnan M, Chiu L, Lam H, et al. Inter-rater reliability in performance status assessment among health care professionals: a systematic review. Ann Palliat Med. 2016;5(2):832–92.
doi: 10.21037/apm.2016.03.02
Disalvo D, Moth E, Soo WK, Garcia MV, Blinman P, Steer C, et al. The effect of comprehensive geriatric assessment on care received, treatment completion, toxicity, cancer-related and geriatric assessment outcomes, and quality of life for older adults receiving systemic anti-cancer treatment: a systematic review. J Geriatr Oncol. 2023;10: 101585.
doi: 10.1016/j.jgo.2023.101585
Magnuson A, Sedrak MS, Gross CP, Tew WP, Klepin HD, Wildes TM, et al. Development and validation of a risk tool for predicting severe toxicity in older adults receiving chemotherapy for early-stage breast cancer. J Clin Oncol. 2021;39(6):608–18.
doi: 10.1200/JCO.20.02063
pubmed: 33444080
pmcid: 8189621
Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326–47.
doi: 10.1200/JCO.2018.78.8687
pubmed: 29782209
pmcid: 6063790